Stem Cells for Knee Osteoarthritis

Knee osteoarthritis is one of the most heavily marketed indications for stem cell injections worldwide, sold both through registered clinical trials and through direct-to-consumer orthopedic and sports medicine clinics. It is also one of the best-studied indications, with enough randomized controlled trials accumulated to support several independent meta-analyses, which makes it a useful test case for how much of the reported benefit is real biological effect versus expectation and ritual.

A 2021 systematic review and meta-analysis published in Arthroscopy pooled 13 randomized controlled trials comparing intra-articular MSC injection against placebo and found no statistically significant difference on any of the four major outcome measures: VAS pain score, WOMAC pain, WOMAC function, or WOMAC stiffness, and none of the point estimates exceeded the minimum clinically important difference threshold [1]. The same analysis found MSC injection performed significantly better than hyaluronic acid injection, the standard viscosupplementation comparator, across VAS pain, WOMAC pain, and WOMAC total scores [1]. In other words, MSCs beat an established alternative treatment but did not clearly beat placebo in that specific pooled dataset.

A more recent and considerably larger 2025 Cochrane systematic review, generally regarded as the most rigorous evidence standard in medicine, pooled 25 randomized trials with 1,341 participants, including 8 trials with a placebo comparator [2]. It found stem cell injection produced a modest improvement over placebo of 1.2 points on a 0-10 pain scale and 14.2 points on a 0-100 function scale, both rated as low-certainty evidence with substantial heterogeneity between trials (I-squared of 80% and 82% respectively) [2]. Serious adverse events were rare and not significantly different between groups, though this finding itself carried only very low certainty given sparse event data [2]. The Cochrane authors' bottom-line conclusion was that stem cell injections 'may slightly improve pain and function' compared with placebo, a considerably more modest claim than typical marketing language implies [2].

The most important nuance in this literature comes from a 2025 systematic review published in Frontiers in Medicine that directly quantified how much of the observed clinical improvement after MSC injection is attributable to contextual effects, meaning the placebo response, the ritual of receiving an injection, and patient expectation, rather than to any biological action of the cells themselves [3]. Pooling 8 randomized trials with 467 total patients, the authors estimated that contextual effects accounted for approximately 63% of the pain reduction (proportion of contextual effect 0.63, 95% CI 0.46 to 0.87, p=0.004) and approximately 61% of the functional improvement (0.61, 95% CI 0.47 to 0.78, p=0.0001) observed at six months [3]. At twelve months, contextual effects explained roughly 50% of pain relief and roughly 66% of functional gain, though the twelve-month functional estimate did not reach statistical significance [3]. All of these estimates carried low GRADE certainty, and a sensitivity analysis showed the six-month pain finding was heavily dependent on the results of a single trial, meaning the exact percentage should be treated as a rough estimate rather than a precise figure [3].

Taken together, these three analyses point to a consistent picture rather than a contradiction: MSC injections for knee osteoarthritis likely produce a real, modest, statistically detectable improvement over placebo in pain and function, on the order of the Cochrane review's 1.2-point pain and 14.2-point function differences, but a substantial share, plausibly half or more, of the total improvement patients experience after any knee injection procedure comes from non-specific contextual and placebo effects rather than the stem cells doing anything unique. This matters directly for anyone evaluating a commercial MSC injection clinic: even honest, well-run programs are working with a treatment whose net specific benefit over an inert injection is small, while an unscrupulous clinic can point to large before-and-after patient improvement numbers that are mostly explained by the injection ritual itself rather than the cell product.

This body of evidence places MSC therapy for knee osteoarthritis in tier 2 of our evidence framework: multiple large randomized trials and rigorous meta-analyses exist, the direction of effect is consistently modestly positive, but the magnitude above placebo is small and the certainty is rated low by Cochrane's own GRADE standard. No MSC product for knee osteoarthritis holds FDA or EMA approval; existing products are used investigationally or through clinics operating in a regulatory gray zone described on our FDA and EMA pages.